接受利妥昔单抗治疗受试者中B细胞再增殖动力学调节协变量的识别
该单中心回顾性观察研究纳入839例因自身免疫病接受2,017疗程利妥昔单抗的受试者,评估年龄、肾功能、基础病及合并免疫抑制对B细胞再增殖(≥5/μl)和重建(≥50/μl)时间的影响。多因素分析显示年龄>60岁、肾功能受损、ANCA相关血管炎、实体器官移植及合并糖皮质激素或硫唑嘌呤与B细胞再增殖和重建受损相关,激素和硫唑嘌呤效应呈剂量依赖性。
要点
- 年龄>60岁(HR 0.71)、肾功能受损(HR 0.72)、ANCA相关血管炎(HR 0.61)、实体器官移植(HR 0.4)与B细胞再增殖受损相关。
- 合并糖皮质激素(HR 0.64)或硫唑嘌呤(HR 0.49)与B细胞再增殖和重建受损相关,效应呈剂量依赖性。
- 作者认为高龄或肾功能受损者可延长利妥昔单抗给药间隔以维持B细胞耗竭并降低感染风险。
核心结论
- 在高龄或肾功能受损患者中,延长利妥昔单抗给药间隔可能有效实现B细胞耗竭并降低感染风险。
- 合并糖皮质激素或硫唑嘌呤延长B细胞恢复,可能增加治疗效果但也增加不良事件发生率。
研究设计与样本
- 单中心回顾性观察研究,纳入839例因自身免疫病接受2,017疗程利妥昔单抗的受试者。
- 评估患者特异性因素(性别、年龄、肾功能、基础病)和合并免疫抑制(硫唑嘌呤、环孢素A、环磷酰胺、羟氯喹、甲氨蝶呤、吗替麦考酚酯、他克莫司、糖皮质激素)。
- 主要终点为B细胞再增殖时间(≥5/μl),次要终点为B细胞重建时间(≥50/μl),采用多因素时间-事件分析和逻辑回归模型。
主要发现
- 年龄>60岁与B细胞再增殖受损相关(HR 0.71,P=0.008)。
- 肾功能受损与B细胞再增殖受损相关(HR 0.72,P=0.001)。
- 抗中性粒细胞胞质抗体相关血管炎与B细胞再增殖受损相关(HR 0.61,P<0.001)。
- 实体器官移植与B细胞再增殖受损相关(HR 0.4,P<0.001)。
- 合并糖皮质激素(HR 0.64,P<0.001)或硫唑嘌呤(HR 0.49,P<0.001)与B细胞再增殖和重建受损相关;糖皮质激素(P=0.043)和硫唑嘌呤(P=0.025)效应呈剂量依赖性。
临床怎么用
- 作者认为在高龄或肾功能受损患者中,延长利妥昔单抗给药间隔可能有效实现B细胞耗竭并降低感染风险。
- 作者认为合并糖皮质激素或硫唑嘌呤延长B细胞恢复,可能增加治疗效果但也增加不良事件发生率。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: B-cell depletion using the anti-CD20 monoclonal antibody rituximab is a cornerstone in the therapeutic concept of multiple autoimmune diseases. B-cell depletion is associated with a higher risk for severe infections, and the time span of B-cell repopulation differs greatly between individuals. Data on factors influencing B-cell repopulation kinetics are limited. This study aims to identify patient-specific and therapy-associated covariates that modulate B-cell repopulation. METHODS: This single-center retrospective observational study presents data of 839 subjects receiving 2,017 courses of rituximab for autoimmune diseases. Assessed covariates are patient-specific factors (sex, age, kidney function, and underlying disease) and co-immunosuppression with common agents (azathioprine, cyclosporine A, cyclophosphamide, hydroxychloroquine, methotrexate, mycophenolate mofetil, tacrolimus, and corticosteroids). The primary end point is the time to B-cell repopulation (≥5/μl). The secondary end point is the time to B-cell reconstitution (≥50/μl). Multivariate time-to-event analysis and logistic regression models were applied to estimate the influence of covariates. RESULTS: Age over 60 years (hazard ratio [HR] 0.71 for repopulation, P = 0.008), impaired kidney function (HR 0.72, P = 0.001), antineutrophil cytoplasmic antibody-associated vasculitis (HR 0.61, P < 0.001), solid organ transplantation (HR 0.4, P < 0.001), and co-immunosuppression with corticosteroids (HR 0.64, P < 0.001) or azathioprine (HR 0.49, P < 0.001) were associated with impaired B-cell repopulation and reconstitution. Effects of corticosteroids (P = 0.043) and azathioprine (P = 0.025) were dose dependent. CONCLUSION: Prolonged rituximab dosing intervals may be effective to achieve B-cell depletion and reduce risk of infection in advanced age or patients with impaired kidney function. Co-medication with corticosteroids or azathioprine prolongs B-cell recovery, which may increase therapeutic effects but also the rate of adverse events.
引用
- Welte T, Westermann L, Kappes J, et al. Identification of Covariates Modulating B-Cell Repopulation Kinetics in Subjects Receiving Rituximab Treatment. Arthritis Rheumatol. 2023. PMID: 37276446. doi:10.1002/art.42625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。